HOME >> BIOLOGY >> NEWS
Miniature spectrometer can detect biological hazards

OAK RIDGE, Tenn., March 17, 2003 Researchers at the Department of Energy's Oak Ridge National Laboratory have developed a miniature device that can identify as little as a fraction of a spore of anthrax and other biological hazards within 30 milliseconds.

The Calorimetric Spectrometer (CalSpec TM) device technology can accurately identify biological hazards such as anthrax almost instantly. The device can operate with only a fraction of a spore while isolating the DNA/RNA photothermal signature that allows for detection, identification and measurement of a substance.

Such prompt detection and identification of hazardous materials could greatly enhance the protection of first-responder emergency personnel and the capabilities of early warning systems. Current technologies do not provide the level of sensitivity offered by the CalSpec TM chemical, biological and DNA/RNA detection system.

Researchers Panos Datskos and Slobodan Rajiic of ORNL's Engineering Science and Technology Division developed the CalSpec TM technology. ORNL has licensed the technology exclusively to Innovative American Technology of Herndon, Va., and Boca Raton, Fla.

The CalSpec TM can detect hazards by identifying their molecules. The molecular absorption can induce stress changes that allow for an initial detection that can be used for measurement. The identification of chemical and/or biological molecules, along with DNA/RNA, creates a photothermal signature.

The spectrometer could have a wide variety of applications in commercial industry and in homeland defense, including mass transit and airport security; in the postal industry, to protect workers and the public; and in monitoring air quality systems.

"The CalSpec TM detection device could provide a cost-effective and easily deployed upgrade for these systems to enable rapid detection, greater accuracy and most important increased sensitivity down to a fraction of a spore," said Jack Cumming
'"/>


17-Mar-2003


Page: 1 2

Related biology news :

1. Miniature biolab embedded on silicon chip
2. Miniature implantable sensor likely lifesaver for patients
3. Scientists Excited About Miniature Cooking Pots
4. Collaboration at EMSL produces innovative mass spectrometer
5. Mass spectrometer weighs in as proteomics breakthrough
6. The worlds most powerful NMR spectrometer
7. New sequence involved in DNA replication timing may aid in cancer detection
8. Scientists find nanowires capable of detecting individual viruses
9. Brain has center for detecting sound motion
10. Early detection hope for eye disease
11. Wrapping a memory with an experience, capacity for recollection detected in non-human species

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Miniature spectrometer can detect biological hazards

(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation ... largest exhibition for service robots ever held in ... takes place on May 11-13, 2015 at the ... exhibitors for the event include: Acorn Product Development; ... EZ-Robot; Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya ...
(Date:3/12/2015)... 2015 WHEN:Tuesday, March 17, 2015 at 11:00 ... . SPEAKERS: , Frost & Sullivan Measurement & ... Biometric companies must plan for ... different markets and industries. This is especially true ... Join Frost & Sullivan,s upcoming ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
(Date:3/30/2015)... PMG Research, Benchmark Research, and Miami ... of VaxCorps, a network of highly experienced, geographically ... of vaccine trials in healthy adult, elderly, and ... conducted over 500 phase I-III vaccine clinical trials, ... as well as a vast array of other ...
(Date:3/30/2015)... 30, 2015  NuGene International, Inc. ("NuGene") (OTCQB: ... BioPharma, Inc. has added another internationally recognized researcher ... is an internationally recognized researcher in bio-inspired materials ... at Peking University, China , ... University of North Carolina, Chapel Hill. Following a ...
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... Md. , March 30, 2015  Spherix ... company committed to the fostering and monetization of ... v. VTech,  Case No. 3:13-cv-03494-M and  Spherix v. ... United States District Court for the Northern District ... update regarding Spherix v. Verizon, Case ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
Cached News: